• Profile
Close

The impact of expanded Medicaid eligibility on access to naloxone

Addiction Apr 19, 2019

Frank RG, et al. - Researchers characterized the differences between 2009 and 2016 in the amount of Medicaid-covered naloxone used, as well as between states that expanded their Medicaid programs and states that did not. Starting in 2014, a quasi-experimental study according to states’ decision to expand their Medicaid program to all adults with incomes between 100% and 138% of the federal poverty line was performed. Thirty-one states had expanded while 14 states that had not, as of 2018. Medicaid-covered naloxone prescriptions were comparable across the states before the expansion, but afterwards states that expanded saw a nearly 10-fold increase in naloxone prescriptions vs the years before expansion. Approximately 25% of naloxone sales were attributed to Medicaid. From 2009 to 2016, they observed 8.3% of the growth in naloxone units was attributable to Medicaid expansion.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay